The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 05, 2017

Filed:

Aug. 16, 2011
Applicants:

Nicolas Fischer, Geneva, CH;

Giovanni Magistrelli, Cessy, FR;

Franck Gueneau, Saint-Julien-en-Genevois, FR;

Ulla Ravn, Geneva, CH;

Greg Elson, Collonges Sous Saleve, FR;

Inventors:

Nicolas Fischer, Geneva, CH;

Giovanni Magistrelli, Cessy, FR;

Franck Gueneau, Saint-Julien-en-Genevois, FR;

Ulla Ravn, Geneva, CH;

Greg Elson, Collonges Sous Saleve, FR;

Assignee:

NOVIMMUNE SA, , CH;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/46 (2006.01); C07K 16/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C12N 15/10 (2006.01);
U.S. Cl.
CPC ...
C07K 16/468 (2013.01); C07K 16/005 (2013.01); C07K 16/248 (2013.01); C07K 16/249 (2013.01); C07K 16/2866 (2013.01); C12N 15/1037 (2013.01); C12N 15/1075 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01);
Abstract

The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other of a Lambda constant domain. The invention provides methods for the isolation of antibodies of different specificities but sharing a common heavy chain. The invention also provides methods for the controlled co-expression of two light chains and a single heavy chain leading to the assembly of monospecific and bispecific antibodies. The invention provides a mean of producing a fully human bispecific and bivalent antibody that is unaltered in sequence and does not involve the use of linkers or other non-human sequences, as well as antibody mixtures of two monospecific antibodies and one bispecific antibody. The invention also provides the means of efficiently purifying the bispecific antibody.


Find Patent Forward Citations

Loading…